Exploring Nd:YAG Vitreolysis After Cataract Surgery for Symptomatic Eyes

Dagny Zhu, MD, a cataract and refractive surgeon in Los Angeles, highlighted her emerging data on the use of Nd:YAG laser vitreolysis as a potential in-office solution for symptomatic vitreous opacities after cataract surgery. In a discussion with host I. Paul Singh, MD, Dr. Zhu shared preliminary findings from an ongoing prospective study in which she is evaluating how Nd:YAG vitreolysis may improve contrast sensitivity and quality of vision in pseudophakic patients bothered by floaters.

Dr. Zhu said her interest in vitreous opacities grew out of a desire to improve her patients’ satisfaction rates following premium cataract procedures. She noticed that floaters are often among the most common postoperative complaints, even when the surgery itself is technically successful. She explained that, although patients frequently attribute these symptoms to the surgery, “Unfortunately, a lot of times [floaters are] preexisting, but sometimes it can be induced by surgery.”

Although pars plana vitrectomy remains an option for severe cases, Dr. Zhu said she began exploring Nd:YAG laser vitreolysis as a less invasive, office-based alternative. Over time, she refined her approach to focus on safety and controlled energy delivery during the procedure. “If you’re doing it properly, it’s always about technique at the end of the day,” she said, adding that she has never experienced a retinal detachment or tear following vitreolysis in her practice.

Much of Dr. Zhu’s technique centers on limiting the treatment energy and carefully selecting patients. Most of her cases involve pseudophakic patients, with treatment concentrated in the anterior or mid-vitreous cavity. “The most important thing that I found is the energy,” she said, noting that she keeps treatment settings at or below 4.0 mJ to avoid postoperative IOP spikes.

The ongoing study, although small, has already shown encouraging trends. According to Dr. Zhu, preliminary data from 10 eyes demonstrated improved contrast sensitivity after a single treatment session, along with statistically significant improvements in patients’ ability to perform daily visual tasks (Figure 1). “It’s nice to have both the subjective and objective data,” she said. “There’s very limited research on contrast sensitivity after Nd:YAG laser vitreolysis.”

The findings may be especially relevant for patients with multifocal IOLs, who often begin with lower baseline contrast sensitivity. “Just removing the culprit, the vitreous, [patients] can keep that multifocal IOL, and they can be happy with their spectacle independence,” Dr. Zhu said.

Although not quantified in the study, Dr. Zhu said she has realized another benefit of adopting Nd:YAG vitreolysis: fewer referrals for pars plana vitrectomy to treat the floaters.

“This benefits my patients by helping them to avoid an invasive procedure with more potential serious side effects, as well as offering a safe, effective, and low-cost alternative to patients who are underinsured or uninsured with limited access to surgeons who perform pars plana vitrectomy for vitreous opacities,” she said.